Status:
TERMINATED
Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors
Lead Sponsor:
Stanford University
Conditions:
Anal, Colon, and Rectal Cancers
Head and Neck Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Cetuximab, erlotinib, and panitumumab are all recently FDA approved epidermal growth factor receptor (EGFR) inhibitors that treat a wide variety of tumor types, such as colon, lung, and head and neck....
Eligibility Criteria
Inclusion
- Patients are eligible if they have histologically proven adenocarcinoma, are planning to or currently undergoing treatment with an anti-EGFR (epidermal growth factor receptor) therapy, and are 18 years of age or older.
Exclusion
- None
Key Trial Info
Start Date :
August 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01137162
Start Date
August 1 2008
End Date
October 1 2011
Last Update
July 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305